Hikal Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/unhg35ezckgzuzivtvbo83i7.pdf

Key Takeaways


The Taloja Disruption

Sameer Hiremath: "We're making alternative arrangements to move products around from one site to the other if and when such unfortunate events do take place in the future."

Pharma: A Demand Air Pocket


Crop Protection: Demand Intact, Supply Disrupted

Vimal Kulshrestha: "Absolutely, we expect so. We expect that some of this capacity will shift to India."

Margins: Compressed Now, Recovery Promised

Manoj Mehrotra: "In the pharma API or the own product business, unfortunately, we have not been able to pass on the cost increases because everyone has not increased the prices. So, there, we have to kind of absorb."

The Growth Bet: Capex, Capacity, and a Pipeline

Sameer Hiremath: "In the last 5 years, maybe we have not grown as fast as our competitors, but you will see, in the next 5 years, we are going to catch up and we'll be playing in the same level as the top two-three in each of our fields."

Customer & Portfolio Resilience

Anish Swadi: "I would like to reiterate that we have not lost a single customer or contract in any of our businesses during this period."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue recoveryMake up lost Q1 revenue; flattish vs FY22 (~₹1,900 crore)FY23 (full year)
Quarterly revenue rampQ2 better than Q1, Q3 better than Q2; average of remaining three quarters above ₹500 croreQ2–Q4 FY23
Pharma sales normalizationSales to start normalizing; full benefit from Q3 and Q4By end of Q2 FY23
Taloja normalizationBack on regular run rate in a staggered mannerQ3 and Q4 FY23
EBITDA margin recoveryDouble-digit EBITDA margin from Q2 onwardsQ2 FY23
Raw material cost benefitFull impact of softening raw material pricesQ3 FY23 onwards
Panoli plant commissioningMultipurpose plant at Panoli operationalEnd of FY23
Animal Health plant commissioningPlant complete; product validation starts following yearEnd of FY23
Margin improvement50–100 bps YoY improvement on margins, using FY22 as baseFY24 onwards
Growth accelerationGrowth accelerating into high teensFY24 and FY25
Panoli peak revenue~₹300 crore peak revenueBy FY26 (3 years post-commissioning)
EBITDA margin targetApproximately 22%–23% EBITDA marginsBy FY25
CDMO revenue mixCDMO to contribute 60% of revenueNo date (target stated)
Largest pharma product weightageReduce from 30% to 20% of pharma revenueLong-term

Key Metrics

MetricQ1 FY23
Revenue₹379 cr, -17% YoY from ₹457 cr
EBITDA₹23 cr, lower due to sales decline, product mix, higher input costs, and under-absorption of fixed costs
PATLoss of ₹8.9 cr, driven by lower operating profits, higher depreciation, and marginal finance cost increase
Pharma division revenue₹224 cr, -18% YoY from ₹274 cr
Pharma division EBITNegative ₹8 cr, due to lower sales, higher input costs, lag in passing costs to customers, and lower fixed cost absorption
Crop Protection division revenue₹155 cr, -15% YoY from ₹183 cr
Crop Protection division EBIT₹10 cr, impacted by lower sales, higher raw material, solvent and energy costs, and lower fixed cost absorption
Taloja plant disruption impact₹50 cr revenue loss, ₹20 cr contribution loss in Q1
Net debt₹680 cr as of June 30, roughly 50% term loan and 50% working capital
Cost of funds increase18 bps in Q1, with further increases expected in Q2 and Q3
Long-term credit ratingA+ by ICRA, maintained
FY23 revenue expectation~₹1,900 cr, flattish vs FY22; Q2–Q4 average quarterly revenue expected above ₹500 cr
Panoli plant peak revenue expectation~₹300 cr at peak, 3 years after commissioning (FY26)
New project margin profileWell in excess of 20% EBITDA, vs historical 18–19%
Pharma largest product concentration~30% of Pharma revenue, long-term target to bring down to 20%